Kyowa Kirin Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020; Provides Second Quarter Dividend and Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2020
May 01, 2020 at 07:30 am
Share
Kyowa Kirin Co., Ltd. reported consolidated earnings results for the first quarter ended March 31, 2020. For the period, the company reported revenue of JPY 77,293 million against JPY 75,835 million a year ago. Core operating income was JPY 16,762 million against JPY 17,334 million a year ago. Profit was JPY 13,842 million or JPY 25.78 per basic share and JPY 25.76 per diluted share against profit of JPY 8,114 million or JPY 14.97 per basic share and JPY 14.95 per diluted share a year ago.
The company provided consolidated earnings guidance for the fiscal year ending December 31, 2020. For the period, the company expects revenue of JPY 327,000 million, core operating profit of JPY 65,000 million and profit of JPY 49,000 million or JPY 91.26 per basic share.
The company expects to pay second quarter dividend of JPY 22.00 per share and year-end dividend of JPY 22.00 per share for the fiscal year ending December 31, 2020.
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Kyowa Kirin Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020; Provides Second Quarter Dividend and Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2020